Press releases

Press releases

22 October 2014  - Paris (France)

Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

10 October 2014  - Paris (France)

Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients

10 October 2014  - Paris (France)

Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer

02 October 2014  - Paris (France)

Susheel Surpal steps down as Executive Vice President, Chief Financial Officer of Ipsen to pursue other opportunities

27 September 2014  - Paris (France)

Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress

01 September 2014  - Paris (France)

Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe

29 August 2014  - Paris (France)

Ipsen: 2014 half-year results and 2014 objectives

27 August 2014  - Basking Ridge (USA)

Ipsen North America Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2014

17 July 2014  - Paris (France)

New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors

11 July 2014  - Paris (France)

Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe